The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC)

Sponsor

Iuliu Hatieganu University of Medicine and Pharmacy (Other)

Overall Status

Completed

CT.gov ID

NCT02839668

Collaborator

Prof. Dr. I. Chiricuta Institute of Oncology (Other)

120

Enrollment

Location

Arms

Actual Duration (Months)

3.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Because neoplastic disease is one of the leading causes of death worldwide and breast cancer is one of the most frequent neoplasia among women, the possibility of influencing the evolution of patients starting from the moment of surgical intervention using a perianesthesic intervention is a scientific topic of high interest. The study will compare two anesthetic techniques and their efficiency in lowering the factors that can favorize the dissemination of neoplasia and their role in the prevention of postoperative pain. The serum level of vascular endothelial growth factor A (VEGF-A) will be determined before and after the surgical intervention after using two different types of anesthesia (inhalational and intravenous), and the immunohistochemical expression of vascular endothelial growth factor receptors (VEGFR) will be determined on the excised tissue. For the two different types of anesthesia a continuous infusion of lidocaine 1% will be associated. The study will compare the short-term and long term-outcome of the patients assigned the two different types of anesthesia and their immediate postoperative evolution .

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer	Drug: Lidocaine Drug: Sevoflurane Drug: TIVA-TCI Drug: Acetaminophen Drug: Tramadol Drug: Neostigmine Drug: Atropine Device: BIS	Phase 2

Detailed Description

The study will enroll patients with ages between 18 and 80 years old, diagnosed with breast cancer but without proof of disease dissemination on medical imaging. After obtaining an informed consent the patients will be computer randomized to 4 groups. Each group will benefit from a certain type of anesthesia. The first group will be assigned general anesthesia using Sevoflurane for maintenance of hypnosis, the second group will be assigned general anesthesia with Sevoflurane and a continuous infusion of lidocaine 1%. The thrid group will be assigned total intravenous anesthesia using propofol for maintenance of hypnosis and the fourth group will be assigned to total intravenous anesthesia with propofol and a continuous infusion of lidocaine 1%. Before the surgical procedure a blood sample will be drawn from each patient for the measurement of serum vascular endothelial growth factor A ( VEGF-A). All the patients will receive pre-medication a night before the intervention with low molecular weight heparin (LMWH) and midazolam 5mg the morning of the intervention. For the first two groups the anesthetic induction will be conducted using propofol 1,5-2 mg/kg, fentanyl 1-3 microg/kg, atracurium 0,5 mg/kg.For the maintenance of anesthesia Sevoflurane will be used at a alveolar concentration of 1-1,5 MAC, as to maintain a BIS between 45-55. Intraoperative anesthesia will be ensured by using fentanyl boluses of 100 microg and the muscular relaxation needed for mechanical ventilation will be maintained using boluses of 10 mg of atracurium. At the end of the surgery the neuromuscular blockade will be antagonized with neostigmine 0.05 mg/kg and atropine 0.2 mg/kg. For the second group at the induction of anesthesia the patient will be administered a bolus of lidocaine 1% of 1.5 mg/kg and a continuous infusion of lidocaine 1% 2 mg/kg/h will be associated throughout the procedure and 1mg/kg/h,24 h postoperative. The postoperative analgesia will be assured by administering acetaminophen 1 g each 8 h and tramadol 25-50 mg each 4-6 h as needed. For the third and fourth groups the induction of aneshesia will be made using propofol administered by target controlled infusion (TCI) technique with a target plasma concentration of 4 microg/ml . Throughout the intervention the plasma concentration of propofol will be adjusted with increments of 0.2 microg/ml as to maintain a BIS between 45-55. To attenuate the response to laryngoscopy the patient will receive a bolus of fentanyl 1-3 microg/ml. During the intervention fentanyl will be administered in boluses of 100microg as needed. Muscular relaxation necessary for intubation will be provided using atracurium 0.5 mg/kg at induction of anesthesia and 10 mg boluses during the surgery as needed. At the end of the surgery the neuromuscular blockade will be antagonized with neostigmine 0.05 mg/kg and atropine 0.2 mg/kg. For the fourth group at the induction of anesthesia the patient will be administered a bolus of lidocaine 1% of 1.5 mg/kg and a continuous infusion of lidocaine 1% 2 mg/kg/h will be associated throughout the procedure and 1mg/kg/h, 24 h postoperative.Postoperative analgesia will be assured by administering acetaminophen 1 g each 8 h and tramadol 25-50 mg each 4-6 h as needed. Throughout the surgical intervention the patients will be monitored accordingly to the American Society of Anesthesiologists (ASA) standards (electrocardiogram-ECG, heart rate- HR, peripheral capillary oxygen saturation- SpO2, non-invasive blood pressure- NIBP, capnography and for the 3rd and 4th groups the bispectral index - BIS will be monitored). In the postoperative period non-invasive blood pressure -NIBP, heart rate- HR,peripheral capillary oxygen saturation SpO2, intensity of pain at 24 and 48 h will be monitored.Vascular endothelial growth factor- VEGF levels will be monitored at 24 h postoperative using ELISA technique. Vascular endothelial growth factor receptors 1 and 2 (VEGFR1 and VEGFR2) will be determined using immunohistochemical staining.

Study Design

Study Type:

Interventional

Actual Enrollment :

120 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Single (Participant)

Primary Purpose:

Basic Science

Official Title:

The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer

Actual Study Start Date :

Aug 1, 2016

Actual Primary Completion Date :

Sep 1, 2019

Actual Study Completion Date :

Sep 1, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Sevoflurane The patients enrolled in this arm will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia	Drug: Sevoflurane maintenance of hypnosis during anaesthesia with sevoflurane Drug: Acetaminophen administration of 1 g acetaminophen for postoperative analgesia Other Names: paracetamol Drug: Tramadol administration of tramadol for postoperative analgesia Other Names: Tramal Drug: Neostigmine A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. Other Names: Prostigmin, vagostigmin Drug: Atropine A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine Other Names: atropine sulfate Device: BIS For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored Other Names: bispectral index monitor
Active Comparator: Sevoflurane+Lidocaine The patients enrolled in this group will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 2 mg/kg/h will be associated throughout the surgical procedure and 1mg/kg/h until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia	Drug: Lidocaine Continuous infusion of lidocaine Other Names: lidocaine 1%, lignocaine Drug: Sevoflurane maintenance of hypnosis during anaesthesia with sevoflurane Drug: Acetaminophen administration of 1 g acetaminophen for postoperative analgesia Other Names: paracetamol Drug: Tramadol administration of tramadol for postoperative analgesia Other Names: Tramal Drug: Neostigmine A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. Other Names: Prostigmin, vagostigmin Drug: Atropine A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine Other Names: atropine sulfate Device: BIS For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored Other Names: bispectral index monitor
Experimental: TIVA-TCI The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine. The bispectral index- BIS will be monitored throughout the anesthesia.	Drug: TIVA-TCI maintenance of hypnosis during anaesthesia with sevoflurane Other Names: Diprivan Drug: Acetaminophen administration of 1 g acetaminophen for postoperative analgesia Other Names: paracetamol Drug: Tramadol administration of tramadol for postoperative analgesia Other Names: Tramal Drug: Neostigmine A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. Other Names: Prostigmin, vagostigmin Drug: Atropine A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine Other Names: atropine sulfate Device: BIS For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored Other Names: bispectral index monitor
Active Comparator: TIVA-TCI+lidocaine The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 2 mg/kg/h will be associated throughout the surgical procedure and 1mg/kg/h until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia.	Drug: Lidocaine Continuous infusion of lidocaine Other Names: lidocaine 1%, lignocaine Drug: TIVA-TCI maintenance of hypnosis during anaesthesia with sevoflurane Other Names: Diprivan Drug: Acetaminophen administration of 1 g acetaminophen for postoperative analgesia Other Names: paracetamol Drug: Tramadol administration of tramadol for postoperative analgesia Other Names: Tramal Drug: Neostigmine A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. Other Names: Prostigmin, vagostigmin Drug: Atropine A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine Other Names: atropine sulfate Device: BIS For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored Other Names: bispectral index monitor

Outcome Measures

Primary Outcome Measures

serum concentration of vascular endothelial growth factor A (VEGF-A) [1 year]

Secondary Outcome Measures

pain score [1 year]
assesed using visual-analogue scale
survival of patients [up to 5 years]
Vascular endothelial growth factor receptor 1 and 2 (VEGFR1 and VEGFR2) density [at the end of the study]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 80 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

diagnosis of breast cancer
ASA risk class I-III
no metastatic disease

Exclusion Criteria:

hepatic, pulmonary metastasis
type I and II diabetes
rheumatoid arthritis
osteoarthritis
ischemic cardiovascular disease (history of myocardial infarction, angina)
peripheral vascular disease
endometriosis
allergies to lidocaine, fentanyl, propofol, sevoflurane, atracurium, midazolam, acetaminophen, tramadol
neuropsychiatric disorders
incapacity of understanding the study
refusal of participation